Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming Guggenheim Healthcare Talks Radiopharmaceuticals Day being held on May 13, 2024 in New York City. Details of the fireside chat are as follows:
新澤西州弗洛勒姆公園，2024年5月8日（GLOBE NEWSWIRE）——專注於癌症治療藥物發現、開發和商業化的後期臨床生物製藥公司Cellectar Biosciences, Inc.（納斯達克股票代碼：CLRB）今天宣佈，Cellectar首席運營官賈羅德·朗科將在即將舉行的爐邊談話中介紹該公司的概況 Guggenheim Healthcare Talks 放射性藥物日將於 2024 年 5 月 13 日在紐約市舉行。爐邊談話的細節如下：
| Date: | Monday, May 13, 2024 |
| Time: | 1:00 pm Eastern Time |
| Webcast: | Click HERE |
| 日期： | 2024 年 5 月 13 日，星期一 |
| 時間： | 美國東部時間下午 1:00 |
| 網絡直播： | 點擊這裏 |
A replay of the presentation will be available on the Events section of the company's investor relations website.
演講的重播將在 活動 公司的一部分 投資者關係 網站。
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
關於 Cellectar Biosciences, Inc.
Cellectar Biosciences是一家處於後期階段的臨床生物製藥公司，專注於獨立和通過研發合作發現和開發治療癌症的專有藥物。該公司的核心目標是利用其專有的磷脂藥物偶聯物（PDC）交付平台開發下一代癌細胞靶向療法，通過減少脫靶效應來提高療效和安全性。
The company's product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
該公司的產品線包括鉛資產iopofosine I 131、一種旨在提供碘131（放射性同位素）靶向輸送的小分子PDC、專有的臨床前PDC化療項目和多個合作的PDC資產。
For more information, please visit and or join the conversation by liking and following us on the company's social media channels: Twitter, LinkedIn, and Facebook.
欲了解更多信息，請訪問 和 或者通過在公司的社交媒體頻道上點贊和關注我們來加入對話： 推特， 領英，以及 Facebook。
Contacts
聯繫人
MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com
媒體：
克萊爾·拉卡格尼娜
Bliss 生物健康
315-765-1462
clacagnina@blissbiohealth.com
INVESTORS:
Chad Kolean
Chief Financial Officer
investors@cellectar.com
投資者：
Chad Kolean
首席財務官
investors@cellectar.com
譯文內容由第三人軟體翻譯。